Literature DB >> 11491146

Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells.

S H Korn1, A Jerre, R Brattsand.   

Abstract

The effect of formoterol, alone and in combination with budesonide, upon tumour necrosis factor-alpha stimulated (10 ng x mL(-1)) human bronchial epithelial cells was investigated. Addition of formoterol (> or = 10(-10) M) reduced granulocyte macrophage-colony stimulating factor (GM-CSF) levels, as assessed by enzyme-linked immunosorbent assay, by 40-50% and increased interleukin (IL)-8 levels by approximately 50%. The effects of formoterol were long lasting (23 h). Budesonide (10(-8) M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%. Simultaneous addition of formoterol and budesonide reduced GM-CSF levels approximately 75%, while IL-8 levels were decreased approximately 40%, similar to the reduction obtained with budesonide alone. The glucocorticoid receptor (GR) antagonist RU486 did not influence the effect of formoterol, suggesting no involvement of the GR. Formoterol rapidly induced an elevation in intracellular cyclic adenosine monophosphate, which was reduced in the presence of propranolol. In addition, the alterations in cytokine secretion induced by formoterol could be fully blocked by propranolol, demonstrating that these effects are beta2-receptor mediated. In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11491146     DOI: 10.1183/09031936.01.00073301

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

Review 1.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 2.  Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; P Bartsch; C-G Löfdahl; W Vincken; R Dekhuijzen; J Vestbo; R Pauwels; R Naeije; T Troosters
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

Review 3.  Interactions between corticosteroids and beta2-agonists.

Authors:  Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

4.  The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations.

Authors:  George R Washko; Vincent S Fan; Scott D Ramsey; Zab Mohsenifar; Fernando Martinez; Barry J Make; Frank C Sciurba; Gerald J Criner; Omar Minai; Malcolm M Decamp; John J Reilly
Journal:  Am J Respir Crit Care Med       Date:  2007-10-25       Impact factor: 21.405

Review 5.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

6.  Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs.

Authors:  Giuseppe Rossoni; Barbara Manfredi; Roberta Razzetti; Maurizio Civelli; Stefano Bongrani; Ferruccio Berti
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 7.  Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Authors:  Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2016-11-09       Impact factor: 8.739

8.  (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS.

Authors:  Brian N Chorley; Yuehua Li; Shijing Fang; Jin-Ah Park; Kenneth B Adler
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

Review 9.  Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.

Authors:  Paul L McCormack; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.